Pershing Square USA and Inc. Begin Trading on April 29
Pershing Square USA and Pershing Square Inc. began trading on April 29, marking the public debut of Bill Ackman's two vehicle structure.LATEST IPOS AND DIRECT LISTINGS:Seaport Therapeuticsopened on May 1 at $21. The company priced 14.2M shares at $18.00. The deal size was increased to 14.2M shares of common stock from 11.8M shares and priced at the high-end of the $16.00-$18.00 range. Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other neuropsychiatric disorders.Hemab Therapeuticsopened on May 1 at $27. The company priced 16.75M shares at $18.00. The deal size was increased to 16.75M shares from 15.0M and priced at the top end of the $16.00-$18.00 target range. Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that it says "reimagine the treatment of blood coagulation disorders to sustain life and human resilience."Avalyn Pharmaopened on April 30 at $26.00. The company priced 16.67M shares at $18.00. The deal priced at the top end of its $16.00-$18.00 target range. Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis.Silver Bow Miningopened on April 30 at $10.75. The company priced 5.2M shares at $11.50. The deal size was increased to 5.2M shares of common stock from 4.35M shares and the deal priced within the $10.00-$13.00 range. Silver Bow Mining is a minerals exploration company focused on developing silver, zinc, gold, lead, and copper targets in the Butte Mining District of Montana.Pershing Square USA, an investment company managed by Pershing Square Capital Management, andPershing Square Inc., the parent company of PSCM, opened for trading on April 29. Pershing Square USApriced its IPO at $50 and opened for trading at $42, while Pershing Square Inc.opened at $24. The Pershing Square USA shares and the Pershing Square Inc. shares trade on the New York Stock Exchange under the symbols "PSUS" and "PS", respectively.RECENT SPAC IPOS:CH4 Natural Solutionsopened on May 1 at $10.00. The blank check company intends to focus its search for a target business with a "significant real-asset footprint that may provide opportunities for attractive risk-adjusted returns and benefit from accelerated methane mitigation initiatives at scale."Quantum Leap Acquisitionopened on May 1 at $10.00. The blank check company intends to focus on target companies within the artificial intelligence, quantum computing, and blockchain technology sectors.General Catalyst Global Resilience Mergeropened on April 30 at $10.05. The blank check company intends to focus on "global resilience" sectors, including aerospace and defense, national security, industrials and manufacturing.RRE Ventures Acquisitionopened on April 30 at $9.97. Cohen and Company Capital Markets is acting as representative of the several underwriters for the offering.Mountain Crest Acquisition 6opened on April 30 at $10. D. Boral Capital is acting as the sole book-running manager for the offering.ARC Group Acquisition Iopened on April 30 at $10.02. The blank check company may pursue an acquisition opportunity in any business, industry, sector or geographical location, but intends to identify and acquire a business "where it believes its management teams' and its affiliates' expertise will provide it with a competitive advantage, including technology, healthcare and logistics industries."West Enclave Mergeropened on April 30 at $10.02. The special purpose acquisition company may pursue a target in any geography or industry and intends to focus on identifying a high-quality business that operates in Latin America or a U.S. based business whose revenues, operations or strategic growth are positioned to benefit from the economic interconnection between the United States and Latin America, particularly Mexico.Forefront Tech Holdings Acquisitionopened on April 30 at $9.98. BTIG is acting as sole book-running manager for the offering.Churchill Capital Corp XIIopened on April 28 at $10.12. The blank check company may pursue an initial business combination target in any business or industry.Plutonian Acquisition Corp IIopened on April 28 at $10.03. Alliance Global Partners is acting as the sole book-running manager for the offering.PERFORMANCE:Prices as of 11:30 am ET on Monday, May 4 -Seaport Therapeutics – down over 7% at $18.13;Hemab Therapeutics – down almost 14% at $29.25;Avalyn Pharma – down about 3.5% at $28.81;Silver Bow Mining – down more than 6% at $10.10;Pershing Square USA – fractionally down at $42.56;Pershing Square Inc. – down almost 10% at $34.35.UPCOMING IPOS:Upcoming IPO and direct listings expected include Csquare, Tarsier Pharma, Quantinuum, Cerebras, Boundless Group, and Liftoff.Clickto see upcoming IPO calendar on TipRanks.Csquarefiled confidentially for a U.S. initial public offering, a signal that more data center companies are lining up to sell shares for the first time over the coming year, Bloomberg's Bailey Lipschultz. The provider of colocation and data center services announced on Friday that it had submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission. The Brookfield Infrastructure Partners-backed company joins a rush of new listings as the companies building out the backbone to support AI's energy needs seek to raise funds, the author notes.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial... Although we are still early in this journey, I believe we have the technology, the team, the discipline, and the persistence required to build an enduring company."Honeywellannounced that Quantinuum, which is majority owned by Honeywell, confidentially submitted a draft registration statement on Form S-1 to the U.S. SEC on February 17, relating to the proposed initial public offering of Quantinuum's common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systemsannounced that it has filed a registration statement on Form S-1 with the U.S. SEC relating to a proposed initial public offering of its Class A common stock. The number of shares of Class A common stock to be offered and the price range for the proposed offering have not yet been determined. Cerebras intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "CBRS." Morgan Stanley, Citigroup, Barclays, and UBS Investment Bank will act as lead book-running managers for the proposed offering. Mizuho and TD Cowen will act as bookrunners. Needham & Company, Craig-Hallum, Wedbush Securities, Rosenblatt, and Academy Securities will act as co-managers.Boundless Group is offering 4M Class A ordinary shares on a firm commitment basis in an initial public offering. The company expects the initial public offering price of its Class A ordinary shares to be in the range of $4.00 to $5.00 per share.Liftoff Mobileannounced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on SPTX
About SPTX
About the author

- Wider Financial Loss: Seaport Therapeutics reported a net loss of $25.41 million for Q1 2026, translating to $10.34 per share, which is a significant increase from last year's loss of $13.13 million or $5.65 per share, indicating ongoing pressures in the market alongside substantial R&D investments.
- Increased R&D Expenses: The R&D expenses for Q1 2026 reached $21.43 million, up from $10.5 million in the same quarter last year, primarily driven by the advancement of GlyphAllo and GlyphAgo into later stages of development, showcasing the company's commitment to innovation in therapeutics.
- Strong Cash Position: As of March 31, 2026, Seaport had $212.6 million in cash, cash equivalents, and investments, which is expected to sustain operations through 2029, reflecting robust financial management and strategic planning.
- Upcoming Milestones: The company anticipates releasing data from the Phase 1 simulation trial of GlyphAllo in the second half of 2026 and expects to present topline data from the BUOY-1 Phase 2b trial for Major Depressive Disorder in the first half of 2027, indicating a proactive approach to clinical development and market readiness.
- Clinical Trial Success: Seaport Therapeutics successfully demonstrated favorable safety and tolerability in the multiple-ascending dose (MAD) portion of its Phase 1 trial for GlyphAgo, supporting further development in patients with generalized anxiety disorder (GAD).
- Dose Selection Support: Seven-day dosing of GlyphAgo achieved therapeutic exposure levels projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, which will aid in dose selection for future clinical trials.
- Future Trial Plans: Seaport plans to initiate a Phase 2a trial in the second half of 2026 to assess GlyphAgo's potential benefits on sleep in anxiety patients, with topline data expected in early 2028, and a Phase 2b trial is set for the first half of 2027.
- Platform Advantages: The development of GlyphAgo leverages PureTech's Glyph platform, showcasing its innovative ability to overcome drug metabolism limitations, and is expected to provide new treatment options for GAD patients, addressing a 20-year gap in new drug approvals in this area.
- Financial Performance: Seaport Therapeutics reported a GAAP EPS of -$10.34 for Q1 2026, indicating ongoing investment in R&D and operations despite financial pressures.
- Cash Reserves: As of March 31, 2026, the company had $212.6 million in cash, cash equivalents, and investments, which is expected to support its operating plans into 2029, ensuring stability for the coming years.
- IPO Success: Following March 31, 2026, Seaport completed its IPO, raising gross proceeds of $260 million, providing crucial funding for further development, although underwriting discounts and other expenses will be deducted.
- Net Loss Comparison: The net loss for Q1 2026 was $25.4 million, compared to a net loss of $13.1 million in Q1 2025, highlighting challenges in financial management and cost control that may affect investor confidence.
- Successful IPO Financing: Seaport Therapeutics completed an upsized IPO in May 2026, raising $260 million in gross proceeds, which will support the company's operations into 2029, reflecting strong market confidence in its neuropsychiatric drug development.
- Clinical Trial Progress: New data from the Phase 1 trial of GlyphAgoTM indicate that a seven-day dosing regimen can achieve therapeutic exposures at doses projected to avoid liver enzyme elevations, potentially reducing or eliminating the need for liver function testing, thereby enhancing patient safety.
- New Board Member Appointment: Dr. Sharon Mates has been appointed to Seaport's Board of Directors; she previously served as the Co-Founder and CEO of Intra-Cellular Therapies, bringing extensive industry experience that is expected to drive the company's strategic development in the neuropsychiatry field.
- Increased R&D Spending: Research and development expenses for Q1 2026 were $21.4 million, significantly up from $10.5 million in Q1 2025, primarily due to accelerated clinical development of GlyphAlloTM and GlyphAgoTM, reflecting the company's ongoing commitment to new drug development.
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.










